A detailed history of Royal Bank Of Canada transactions in Nektar Therapeutics stock. As of the latest transaction made, Royal Bank Of Canada holds 17,132 shares of NKTR stock, worth $20,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,132
Previous 340 4938.82%
Holding current value
$20,044
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $15,112 - $30,729
16,792 Added 4938.82%
17,132 $21,000
Q1 2024

May 15, 2024

SELL
$0.49 - $0.96 $196 - $384
-401 Reduced 54.12%
340 $0
Q4 2023

Feb 14, 2024

BUY
$0.42 - $0.57 $269 - $365
641 Added 641.0%
741 $0
Q3 2023

Nov 14, 2023

SELL
$0.51 - $1.05 $139 - $287
-274 Reduced 73.26%
100 $0
Q2 2023

Aug 14, 2023

SELL
$0.53 - $1.03 $6,344 - $12,329
-11,970 Reduced 96.97%
374 $0
Q1 2023

May 15, 2023

SELL
$0.64 - $3.15 $14,949 - $73,577
-23,358 Reduced 65.42%
12,344 $8,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $40,778 - $85,976
20,088 Added 128.65%
35,702 $80,000
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $21,997 - $37,193
7,236 Added 86.37%
15,614 $50,000
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $17,558 - $34,175
-5,539 Reduced 39.8%
8,378 $32,000
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $41,146 - $135,704
9,891 Added 245.68%
13,917 $75,000
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $131,053 - $222,779
-12,101 Reduced 75.04%
4,026 $55,000
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $26,662 - $38,433
2,040 Added 14.48%
16,127 $290,000
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $232,717 - $287,374
14,087 New
14,087 $242,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.